๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

19 results for โ€œBialโ€ Clear

  1. 600 mg Ibuprofen

    United Therapeutics Europe Ltd

    Tibial Fractures

    phase 3 small molecule active

    1 trial

  2. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial Portela & Companhia S.A.

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  3. PSMA-11 kit for Ga-68 labelling

    Bial Portela & Companhia S.A.

    Intermediate and high-risk prostate cancer

    phase 3 small molecule active

    1 trial

  4. Placebo, Atoris, 40 mg, tabletki powlekane

    Bial Portela & Companhia S.A.

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  5. Placebo, Minirin, 4 mikrogramy/ml, roztwรณr do wstrzykiwaล„

    Bial Portela & Companhia S.A.

    Rare and ultra-rare glomerulonephritis

    phase 3 small molecule active

    1 trial

  6. Zovirax 50 mg/g crema, Lipovir 50 mg/g Gel, Placebo

    Pharma Mar S.A.

    Recurrent herpes labialis (RHL)

    phase 3 small molecule active

    1 trial

  7. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  8. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial

  9. CPK850

    Novartis Ophthalmics Europe

    Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene

    phase 2 small molecule active

    1 trial

  10. DB-OTO

    Regeneron UK Limited

    Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

    phase 2 gene therapy active

    1 trial

  11. DB-OTO

    Pharma Mar S.A.

    Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)

    phase 2 small molecule active

    1 trial

  12. Placebo, GLUCOPHAGE 500 mg tabletki powlekane

    Bial Portela & Companhia S.A.

    idiopathic infertility

    phase 2 small molecule active

    1 trial

  13. autologous mesenchymal stem cells implantation

    Teva Pharma GmbH

    Tibial Fracture

    phase 2 other completed

    1 trial

  14. BC-101

    BRIGHT MINDS BIOSCIENCES INC.

    Nasolabial Fold Wrinkles

    phase 1 mab active

    1 trial

  15. Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentinยฎ Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions

    BIAL - Portela & Ca

    No medical condition.

    phase 1 other active

    1 trial

  16. Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.

    BIAL - Portela & Ca

    No medical condition.

    phase 1 other active

    1 trial

  17. Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.

    BIAL - Portela & Ca

    No medical condition.

    phase 1 other active

    1 trial

  18. Drug-Drug Interaction Study With BIA 28-6156 and Clarithromycin, Midazolam, and Dabigatran Etexilate in Healthy Participants

    BIAL - Portela & Ca

    Healthy volunteers

    phase 1 other active

    1 trial

  19. Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources